Bin-Hui Chen

Polyol Pathway Inhibition by Epalrestat Attenuates Pathological Bone Loss through Redox Homeostasis and Sorbitol-Linked Calcium Signaling.

The contribution of polyol metabolism to pathological bone remodeling remains incompletely understood. Here, we examined its role in osteoclastogenesis and evaluated the skeletal effects of epalrestat, a clinically approved aldose reductase inhibitor. Exploratory single-cell analysis of two human femoral-head specimens...